AU1146401A - Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system - Google Patents

Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system

Info

Publication number
AU1146401A
AU1146401A AU11464/01A AU1146401A AU1146401A AU 1146401 A AU1146401 A AU 1146401A AU 11464/01 A AU11464/01 A AU 11464/01A AU 1146401 A AU1146401 A AU 1146401A AU 1146401 A AU1146401 A AU 1146401A
Authority
AU
Australia
Prior art keywords
receptor agonists
respiratory system
rhythm disorders
treating genetic
serotonine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11464/01A
Inventor
Diethelm Wolfgang Richter
Bernd Wilken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1146401A publication Critical patent/AU1146401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU11464/01A 1999-11-08 2000-11-08 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system Abandoned AU1146401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19953625 1999-11-08
DE19953625A DE19953625A1 (en) 1999-11-08 1999-11-08 Use of 5HT-1A serotonin receptor agonists for the treatment of genetic or functional respiratory rhythm disorders
PCT/EP2000/011031 WO2001034124A2 (en) 1999-11-08 2000-11-08 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system

Publications (1)

Publication Number Publication Date
AU1146401A true AU1146401A (en) 2001-06-06

Family

ID=7928252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11464/01A Abandoned AU1146401A (en) 1999-11-08 2000-11-08 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system

Country Status (3)

Country Link
AU (1) AU1146401A (en)
DE (1) DE19953625A1 (en)
WO (1) WO2001034124A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130168A1 (en) * 2001-06-22 2003-01-23 Richter Diethelm Wolfgang Use of 5-hydroxytryptamine 4 or 5-hydroxytryptamine 7 agonists to treat or prevent genetic or functional breathing rhythm disorders
WO2005004865A1 (en) * 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
WO2007019880A1 (en) * 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
EP1937255A4 (en) * 2005-09-14 2013-06-26 Univ Witwatersrand Jhb Pharmaceutical composition
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
WO2015127556A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97053A (en) * 1990-02-12 1995-10-31 Bristol Meyers Squibb Co Pharmaceutical compositions comprising azapirones for the treatment of sleep apneas
AU4683499A (en) * 1998-07-30 2000-02-21 Bristol-Myers Squibb Company Improved method for treatment of sleep-related respiratory disorders

Also Published As

Publication number Publication date
WO2001034124A2 (en) 2001-05-17
DE19953625A1 (en) 2001-05-17
WO2001034124A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU8769098A (en) System for treating patients with anxiety disorders
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
EP1036573A4 (en) Device for delivering drug through skin or mucosa
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU6910600A (en) Methods for the treatment of mental disorders
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
IL153236A0 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DE59903751D1 (en) 2 ', 2'-DIFLUORNUCLEOSIDES FOR IMMUNOSUPPRESSIVE THERAPY AND COMBINATION PREPARATES
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
AU1146401A (en) Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU4707101A (en) Method and system for online third party referral system customized to the purchaser's needs
AU7111400A (en) System and method for the diagnosis of respiratory disorders
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
AU7449698A (en) Therapeutic agents for respiratory diseases
NZ316940A (en) Carboxylic acid derivatives, their preparation and their use for the treatment of endothelin receptor disorders
AU6991300A (en) Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract
IL160555A0 (en) Use of snps of mch-r for identifying genetic disorders in maintaining the normal body weight
EP1225950A4 (en) Delivery system for therapy comprising hollow seeds, preferably metal, and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase